News
MTNB
0.5025
-8.64%
-0.0475
Weekly Report: what happened at MTNB last week (0330-0403)?
Weekly Report · 1d ago
Matinas BioPharma receives notice from NYSE
Seeking Alpha · 4d ago
Matinas BioPharma Faces NYSE American Listing Compliance Notice
TipRanks · 4d ago
Matinas BioPharma Hldgs Q4 EPS $(0.26) Up From $(1.68) YoY
Benzinga · 03/31 22:50
Weekly Report: what happened at MTNB last week (0323-0327)?
Weekly Report · 03/30 10:30
Weekly Report: what happened at MTNB last week (0316-0320)?
Weekly Report · 03/23 10:26
Weekly Report: what happened at MTNB last week (0309-0313)?
Weekly Report · 03/16 10:25
Weekly Report: what happened at MTNB last week (0302-0306)?
Weekly Report · 03/09 10:26
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 03/04 12:05
Weekly Report: what happened at MTNB last week (0223-0227)?
Weekly Report · 03/02 10:25
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 02/26 12:05
Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 02/26 09:38
Weekly Report: what happened at MTNB last week (0216-0220)?
Weekly Report · 02/23 10:25
Weekly Report: what happened at MTNB last week (0209-0213)?
Weekly Report · 02/16 10:25
Weekly Report: what happened at MTNB last week (0202-0206)?
Weekly Report · 02/09 10:26
Weekly Report: what happened at MTNB last week (0126-0130)?
Weekly Report · 02/02 10:26
Weekly Report: what happened at MTNB last week (0119-0123)?
Weekly Report · 01/26 10:26
Matinas BioPharma CEO Named Interim Chief Financial Officer
TipRanks · 01/23 22:49
Matinas BioPharma CFO Keith Kucinski Resigns; CEO Jerome Jabbour Appointed Interim CFO
Benzinga · 01/23 22:08
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/23 17:05
More
Webull provides a variety of real-time MTNB stock news. You can receive the latest news about Matinas Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About MTNB
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.